Cyclo Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Cyclo Therapeutics

16/05/2024 14:53

* Cyclo Therapeutics Inc  CYTH.OQ  reported a quarterly
adjusted
loss of 15 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -46 cents.  The mean expectation of two analysts
for the quarter was for a loss of 20 cents per share. Wall
Street expected results to range from -21 cents to -20 cents per
share.
    * Revenue rose 32.9% to $202.00 thousand from a year ago;
analysts
expected $376.67 thousand. 
    * Cyclo Therapeutics Inc's reported EPS for the quarter was
a loss
of 15 cents​.
    * The company reported a quarterly loss of $4.34 million.
    * Cyclo Therapeutics Inc shares had risen by 2.9% this
quarter and
lost 10.1% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Cyclo
Therapeutics Inc is $3.00 
This summary was machine generated from LSEG data May 16 at
01:53 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.20          -0.15          Beat
                                  -0.34          
                                  -0.29          
 Jun. 30 2023      -0.44          -0.33          Beat